Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Celecoxib and Peg-Interferon alpha-2b in NF1
NCT00846430Phase 2Completed
- Sponsor
- Corewell Health
- Start
- Oct 2008
- Primary completion
- Apr 2017
- Modality
- Polymer-based Nanoparticles, Orthosteric Ligands, Cytokines & Interferons
- Countries
- 1
01
Overview
A Phase 2 trial of celecoxib, peginterferon alfa-2b in neurofibromatosis type 1 (NF1), sponsored by Corewell Health. Started Oct 2008; status: completed.
02
Drugs
celecoxibpeginterferon alfa-2b
03
Conditions
neurofibromatosis type 1 (NF1)
Beyond the preview
Go deeper on NCT00846430.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00846430.